SCHEDULE 13G/A: BlackRock Discloses 7.0% Stake in Verve Therapeutics in Amended SEC Filing
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Verve Therapeutics, Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 6,177,751 shares of Verve Therapeutics, Inc. common stock.
- This ownership represents 7.0% of the total outstanding common stock of Verve Therapeutics, Inc.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported ownership position.
- BlackRock holds sole voting power over 6,054,915 shares and sole dispositive power over 6,177,751 shares.
- The shares are held in the ordinary course of business and are not intended for the purpose of changing or influencing control of Verve Therapeutics, Inc.
- BlackRock Investment Management, LLC, a subsidiary of BlackRock, Inc., is identified as an entity within the BlackRock group that beneficially owns 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G Amendment) disclosing an institutional investor's passive ownership stake. It contains no information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- BlackRock, a major institutional investor, holds a significant stake, which can be interpreted as a vote of confidence in Verve Therapeutics.
- The filing explicitly states that the shares are held in the ordinary course of business, suggesting a passive, long-term investment perspective rather than an activist stance.
Future Outlook
NA
Management Comments
- "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Spencer Fleming, Managing Director of BlackRock, Inc.)
Industry Context
This filing reflects a standard regulatory disclosure by a large asset manager, BlackRock, regarding its passive investment in a publicly traded company, Verve Therapeutics, Inc. Such filings are routine for institutional investors crossing certain ownership thresholds and do not inherently indicate specific industry trends beyond general investment activity in the market.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | Previous attorneys-in-fact under the April 30, 2023 Power of Attorney | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | January 21, 2025 | New Power of Attorney issued, revoking previous one to update authorized signatories for regulatory filings. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, which revokes the previous Power of Attorney dated April 30, 2023. This new document authorizes specific individuals to execute SEC filings and other regulatory documents on behalf of BlackRock and its subsidiaries. | January 21, 2025 | This is an internal corporate governance update for BlackRock, ensuring proper authorization for regulatory filings. It does not directly impact Verve Therapeutics' corporate governance. |
Stakeholder Impact
- Shareholders: BlackRock's significant stake (7.0%) indicates a large institutional investor's confidence, which might be viewed positively by other shareholders. The passive nature of the investment (not for control) suggests stability in the ownership structure.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previous Power of Attorney that was revoked. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end). |
| 04/17/2025 | Date of filing/signature of the Schedule 13G Amendment. |
Keywords
Verve Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.